CorMedix, Inc. (CRMD) Stock: A Biotechnology Stock That’s Headed Up – iWatch Markets

CorMedix, Inc. (CRMD) is making a move up in the market today. The company, focused in the biotechnology industry, is currently priced at $7.33 after a move up of 8.75% so far today....

A member of light-sensitive protein family plays role in adjusting skin color

A team of Brown University researchers found that opsin 3 -- a protein closely related to rhodopsin, the protein that enables low-light vision -- has a role in adjusting the amount of pigment produced...

Clinical trial at IU School of Medicine improves treatment of genetic rickets

Credit: Indiana University School of Medicine A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of...

GENcast: Explore, Learn, and Collaborate on Viral Safety in Biomanufacturing

Ask the average person on the street what they think of after hearing the phrase viral safety, and you will most likely be regaled with stories about scientists in hazmat suits saving Matt Damon...

This Biotech Detects Fraudulent Food by Checking its DNA

Spun out of the University of Milano-Bicocca, the Italian biotech Fem2-Ambiente aids in the fight against food contamination and fraud by sequencing DNA traces from food samples. Mission: To use DNA barcoding to make sure...

Marine natural compounds could be potential treatments for triple negative breast cancer

The oceans cover more than 70 percent of the earth's surface and provide a rich source of unique, bioactive natural products. Their chemical diversity and structural complexity represent an untapped supply of potential new...

Healthcare And Biotechnology Dashboard – Update – Seeking Alpha

Executive summary This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Biotechnology looks significantly underpriced relative to historical...

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s learned on the journey...

Hedging success – European Biotechnology

Although the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring theme at the event...

Genentech, Parvus Therapeutics Launch Up-to-$800M Autoimmune Collaboration

Genentech, a Member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel disease (IBD), autoimmune liver diseases (ALD), and celiac...